Modulators of inflammation in Bronchopulmonary Dysplasia

Area of Science:

• Neonatal Medicine
• Pediatric Pulmonology
• Developmental Biology

Background:

• Bronchopulmonary Dysplasia (BPD) affects 30-50% of preterm infants under 1000g.
• BPD results from ventilator and oxygen-induced lung injury, leading to inflammation and abnormal lung development.
• High morbidity and mortality rates underscore the need for effective BPD interventions.

Purpose of the Study:

• To review established and promising anti-inflammatory strategies for BPD prevention and treatment.
• To highlight the role of inflammation, growth factors, and cytokines in BPD pathogenesis.
• To assess the potential impact of anti-inflammatory therapies on BPD outcomes.

Main Methods:

• Literature review of anti-inflammatory approaches for BPD.
• Analysis of studies investigating the mechanisms of BPD development.
• Examination of clinical trials and preclinical research on BPD therapies.

Main Results:

• Inflammation is a key factor in BPD development.
• Dysregulated angiogenesis and alveolarization are hallmarks of BPD.
• Various anti-inflammatory agents have been explored for BPD management.

Conclusions:

• Targeting inflammation holds significant promise for reducing BPD incidence and severity.
• Further research into anti-inflammatory therapies could improve outcomes for preterm infants.
• Effective BPD treatments can decrease long-term morbidity, mortality, and healthcare costs.